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Abstract 
 
Background and objectives: Philadelphia negative chronic myeloproliferative neoplasms (MPN) 
consist of polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis 
(PMF). Clinical information, from India, on these diseases is limited. We sought to undertake a 
descriptive study of these disorders with emphasis on the thrombotic complications. Methods: A 
retrospective chart review of patients who had presented to our institution and had undergone 
testing for JAK2 mutation analysis was undertaken. Results: A total of 227 patients were 
analyzed and the most common diagnosis was polycythemia vera, 42%, followed by PMF 21% 
and ET 13.7%, and 12% of patients had probable MPN. Overall there was a male predominance 
(78.9%), except in patients with ET. Thrombosis (19.4%) and splenomegaly (11.7%) were the 
commonest presenting features.  Arterial thrombosis was present in 35.77% of patients with 
probable MPN, 29.9% of PV and 25.8% of ET. Venous thrombosis was present in 17.8% of 
patients and was most frequent in ET (22.6%). The prevalence of JAK2 positivity was PV 
66.7%, ET 58.1% and PMF 47.9%. Hydroxyurea and venesection were the commonest first-line 
treatment modalities. Most of the patients had at least a partial response to treatment. 
Conclusions: Polycythemia vera was the commonest MPN and the incidence of thrombosis was 
high in the group studied. JAK2 positivity in PV was lower than what has been reported. 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
Introduction 
 
The common Philadelphia negative myeloproliferative neoplasms (MPNs) are 
polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis 
(PMF).54 These present with clinical manifestations and consequent complications of 
‘myeloproliferation’ such as a high hemoglobin, WBC count, platelet count, 
splenomegaly and thrombosis, respectively. The JAK2V617F mutation is a recurrent, 
clonal abnormality seen with varying prevalence in these disorders it leads to constitutive 
tyrosine phosphorylation activity that promotes cytokine hypersensitivity.8 Indian data on 
these diseases is limited82-89 and hence we sought to undertake an analysis of the patients 
who had presented to us for evaluation of these diseases.  
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Review of Literature 
 
The common Philadelphia negative myeloproliferative neoplasms (MPNs) are: 54  
1. Primary myelofibrosis (PMF) 
2. Essential thrombocythemia (ET)  
3. Polycythemia vera (PV)  
These disorders present with ‘myeloproliferation’ such that either the myeloid, red cell, or the 
platelet series, respectively, are proliferating. Although the pathogenesis of these disorders is 
based on mutations, e.g. the JAK2 mutation, which lead to the proliferation of these elements in 
the bone marrow, the clinical manifestations of these mutations are varied. The cause of this 
‘phenotypic variability’ is not completely understood.  
 
Current classification and terminology of MPNs, as per the World Health Organization 
(WHO) classification 2008 
The current WHO classification (2008) of tumours of hematopoietic and lymphoid tissues made 
the following changes in the terminology and classification of the myeloproliferative neoplasms. 
1. The term “disease” was replaced by “neoplasm” and hence “Chronic myeloproliferative 
disease [CMPD]” was replaced by “myeloproliferative neoplasm [MPN]” 
“Myelodysplastic syndrome/myeloproliferative disease [MDS/MPD]” was replaced by 
“Myelodysplastic syndrome/myeloproliferative neoplasm [MDS/MPN]”. 
2. Mast cell disease (MCD) was formally included in the “MPN” category. 
3. Chronic eosinophilic leukemia-not otherwise specified [CEL-NOS] has been maintained 
within the MPN category.  
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4. The fact that the phenotypic diversity of MPNs is due to differences in the specific 
genetic rearrangements or mutation(s) that underlie the clonal myeloproliferation has 
been recognized and hence “Myeloid and lymphoid neoplasms with eosinophilia and 
abnormalities of PDGFRA, PDGFRB, and FGFR1” has been included as a separate 
category which includes molecularly distinct subcategories. This is especially so since 
those patients who harbour a PDGFR mutation, respond to Imatinib. On similar lines, the 
diagnostic criteria for PV, ET, and PMF incorporate molecular markers such 
as JAK2 and MPL mutations.  
The details of current diagnostic criteria of PV, ET and PMF have been mentioned in 
appendix on page 83. 
 
Polycythemia vera79  
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by increased red 
blood cell production independent of the mechanisms that normally regulate erythropoiesis. The 
reported annual incidence of PV increases with advanced age and varies from 0.7 to 2.6 per 
100,000 inhabitants in Europe and North America, but it is much lower in Japan. There is a slight 
male preponderance with the M: F ratio ranging from 1-2:1. The median age of diagnosis is 60 
years, and patients younger than 20 years old are only rarely reported. The underlying cause is 
unknown in most cases. A genetic predisposition has been reported in some families. Ionizing 
radiation and occupational exposure to toxins have been suggested as possible causes in 
occasional patients.  
Three phases of PV may be recognized:  
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(1) A prodromal, pre-polycythemic phase characterized by borderline to only mild 
erythrocytosis 
(2) An overt polycythemic phase, associated with a significantly increased red cell mass, and 
(3) A “spent” or post-polycythemic myelofibrosis phase (post-PV MF) in which cytopenias, 
including anemia, are associated with ineffective hematopoiesis, bone marrow (BM) 
fibrosis, extra-medullary hematopoiesis (EMH), and hypersplenism. 
Clinical features 
The major symptoms of PV are related to hypertension or vascular abnormalities caused by the 
increased red cell mass. In nearly 20% of patients an episode of venous or arterial thrombosis is 
documented. Headache, dizziness, visual disturbances and paresthesias are major complaints and 
gout, pruritus and erythromelalgia are also common. In the full-blown polycythemic stage 
physical findings include plethora and palpable splenomegaly in 70% and hepatomegaly in 40% 
of patients. 
Prognosis 
With currently available treatment, median survival times >10 years are commonly reported. 
Most patients die from thrombosis or hemorrhage, but up to 20% succumb to myelodysplasia 
(MDS) or acute myeloid leukemia (AML). The incidence of MDS or AML is only 2-3% in 
patients who have not been treated with cytotoxic agents, but increases to 10% or more following 
certain types of chemotherapy. 
Post PV MF: 
The probability of evolution to PPMF was 16% at 10 years and 34% at 15 years.  The actuarial 
probability of PPMF at 15 years was higher in those patients presenting at diagnosis with 
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endogenous megakaryocytic colony formation, an elevated serum lactate dehydrogenase (LDH) 
level, and in those who were heterozygous for the JAK2 V617F mutation.72   
 
Primary myelofibrosis (PMF)79  
PMF is a clonal myeloproliferative neoplasm characterized by a proliferation of predominantly 
megakaryocytes and granulocytes in the bone marrow (BM) that in fully developed disease is 
associated with reactive deposition of fibrous connective tissue and with extramedullary 
hematopoiesis (EMH). There is stepwise evolution from an initial prefibrotic phase characterized 
by a hypercellular BM with absent or minimal reticulin fibrosis to a fibrotic phase with marked 
reticulin or collagen fibrosis in the BM and often osteosclerosis. This fibrotic stage of PMF is 
characterized by leukoerythroblastosis in the blood with tear drop-shaped red cells, and by 
hepatomegaly and splenomegaly.  
The overt fibrotic phase is estimated to occur at 0.5-1.5 per 100,000 persons per year. It occurs 
most commonly in the sixth to seventh decade of life, and both sexes are nearly equally affected. 
Children are rarely affected. The etiologic factors responsible for the disease are unknown in the 
majority of patients. Exposure to benzene or ionizing radiation has been documented in some 
cases. Rare familial cases of BM fibrosis in young children have been reported. 
Clinical features 
Up to 30% of patients are asymptomatic at the time of diagnosis and are incidentally discovered 
to have splenomegaly, anemia, leukocytosis or thrombocytosis. Constitutional symptoms may 
include fatigue, dyspnoea, weight loss, night sweats and low-grade fever and bleeding disorders. 
Gouty arthritis and renal stones due to hyperuricemia may also occur. 
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Prognosis 
The time of survival in patients with PMF ranges from months to decades and it depends on the 
stage in which PMF is first diagnosed. The median survival time is 3-7 years in patients 
diagnosed in the fibrotic stage, which contrasts with a 10-year relative survival rate of 72% in 
patients diagnosed in the early prefibrotic phase. Factors at presentation that adversely affect 
prognosis include age >70 years, Hb <10 gm/dl, platelet count <100x106 /L and an abnormal 
karyotype. The major causes of morbidity and mortality are BM failure, thromboembolic events, 
portal hypertension, cardiac failure and acute leukemia which occurs in 5-30% of patients. 
 
Essential thrombocythemia (ET)79  
ET is a chronic MPN that involves primarily the megakaryocytic lineage. It is characterized by 
sustained thrombocytosis ≥450x 109 /L in the peripheral blood, increased numbers of large, 
mature megakaryocytes in the BM, and clinically by episodes of thrombosis and/or hemorrhage. 
Because there is no biologic or genetic marker specific for ET, other causes for thrombocytosis 
must be excluded, including other MPN, inflammatory and infectious disorders, hemorrhage and 
other types of hematopoietic and non-hematopoietic neoplasms. 
Epidemiology 
The true incidence of ET is unknown, but when diagnosed as per the Polycythemia Vera Study 
Group (PSVG) guidelines, it is estimated to be 0.6-2.5 per 100,000 persons per year. Most cases 
occur in patients 50-60 years of age with no sex predilection. ET can be infrequently seen in 
children, but must be distinguished from rare cases hereditary thrombocytosis. The etiology of 
ET is unknown. 
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Clinical features 
More than 50% of the patients are asymptomatic and are diagnosed incidentally. Others are 
diagnosed due to thrombotic or hemorrhagic complications. On evaluation few have 
splenomegaly and 15-20% have hepatomegaly. 
 
Ph-negative MPN in children 
MPNs in general, are less frequent in children and the JAK2 V617F mutation in children with 
PV is significantly less frequent than in adult PV. Children with PV and ET also have a 
significantly lower incidence of thrombosis than adults.69  
 
Thrombosis and bleeding 
A complication which is seen in all the three disorders is bleeding or thrombosis. 
Thrombohemorrhagic complications are a major cause of morbidity and mortality in these 
disorders.3 In PV, patients are prone to thrombosis whereas in PMF and ET there are more 
hemorrhagic problems11 The pathogenesis of these complications is multifactorial and the 
relevance of different pathogenetic factors is not completely understood.  
 
A. Incidence of thrombotic events 
In PV, fatal and nonfatal arterial and venous thromboses are seen in 41% of patients.5  
Thrombotic events have been documented to occur more frequently in the 2 years preceding 
diagnosis. This suggests a causal relationship between the latent myeloproliferative disorder and 
the vascular event. 5 In ET, the incidence of thrombosis and microvascular disturbances or 
hemorrhage is 8.1% per patient‐year and 2.5% per patient‐year, respectively.21  
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B. Significance of thrombotic events 
Thrombotic events increase the mortality in these diseases.6 In a large European study on 
polycythemia (ECLAP trial) the rates of total mortality and mortality from cardiovascular (CV) 
disease and leukemia were much higher than those expected in the general population (1.2, 1.4, 
and 36.1 times respectively).18 
 
C. Factors associated with thrombosis in Philadelphia-negative myeloproliferative diseases 
1. Individual variations: 11  
Some individuals with MPN exhibit a pattern of either exclusively bleeding or thrombotic 
events; many others have both bleeding and thrombosis during the course of their disease. 
Furthermore a patient with an MPN may apparently shift from having predominant bleeding 
complications to being thrombosis prone, or vice versa, as the disease progresses. 
A prior history of thrombotic event is a strong predictive factor for new thrombotic events during 
follow-up. 18 
 
2. Age and prior thrombotic events1, 5, 76:  
Increasing age increases the risk of thrombosis in ET and PV  
 
3. Smoking and hypertension2 : 
These are associated with an increased risk of thrombotic events. 
 
4. RBC abnormalities:  
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Uncontrolled polycythemia: due to increased blood viscosity and the resulting axial migration of 
RBCs may predispose to thrombosis.10, 11 In these patients if the hematocrit is corrected to 
normal by phlebotomy, the major arterial and venous thrombotic complications are reduced.17  
 
Biochemical changes in RBCs: Not only a higher hemoglobin, but biochemical changes in the 
cell membrane and content may also independently impair blood flow. This occurs through the 
formation of RBC aggregates that have the potential to directly block blood flow in small 
vessels. This contributes to ischemia and infarction, especially in the cerebral blood flow.15  
 
Effect of a high hematocrit on platelet function: Platelet adhesion and thrombus formation also 
increase as the hematocrit values increase from 10 to 70 percent.19  
 
5. Neutrophil (polymorphonuclear cells, PMN) abnormalities:  
Leukocytosis: There is a linear correlation between WBC counts and thrombosis (especially 
myocardial infarction) in both ET and PV.1, 2, 76  
 
Activated neutrophils: In ET and PV, a series of PMN activation parameters (PMN membrane 
CD11b and leukocyte alkaline phosphatase [LAP] antigen expression, cellular elastase content, 
plasma elastase, and myeloperoxidase levels) have been studied.10 The interplay between 
activated PMN and activated platelets generates PMN/platelet-mixed aggregates. These are 
known to be increased in several pathological conditions associated with a propensity to 
thrombosis.15   
 
20 
 
6. Platelets 
Thrombocytosis: In one analysis the platelet number did not have a significant association with 
thrombosis in ET.1 But thrombocytosis may be contributing to the vascular events of ET or PV, 
as suggested by the evidence that platelet count reduction lowers the risk of microcirculatory 
disturbances.15 On the other hand, marked thrombocytosis could favor hemorrhagic rather than 
thrombotic manifestations in ET patients. 15  
 
Functional platelet abnormalities: Platelets in thrombocythemia (ET and PV) are hypersensitive. 
Due to the existing high shear stress in the microvasculature (end-arterial circulation), platelets 
spontaneously activate and secrete their products. They form aggregates mediated by von 
Willebrand factor (vWF). These transiently plug the microcirculation, deaggregate, and then 
recirculate as exhausted defective platelets with secondary storage pool disease on ex vivo 
analysis. Thus platelets in these conditions are in a state of activation. At increasing platelet 
counts from below to above 1000 x 10 (9)/l, the thrombotic condition changes into an overt 
spontaneous bleeding tendency as a result of a functional vWF deficiency that is caused by 
proteolysis of large vWF multimers.11, 31 These events are due to functional abnormalities in 
these disorders. These complications are seen in patients with reactive or secondary 
polycythemia and thrombocytosis. But in polycythemia vera, essential thrombocytosis and 
idiopathic myelofibrosis these are probably an effect of the abnormal clone of cells. Especially 
since some features like erythromelalgia never occurs in secondary thrombocytosis15  
 
Platelet microparticles (PMP): After activation of platelets with certain stimuli, there is a release 
of vesicular particles called platelet microparticles. These microparticles have been shown to 
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accelerate thrombin generation.62 Patients with a history of venous or arterial thrombotic events 
have been shown to have more circulating microparticles than patients without thrombosis.50  
 
7. Endothelial damage:  
In ET and PV increased levels of thrombomodulin and von Willebrand factor antigen have been 
found. This suggests that there is a contribution from endothelial damage to thrombosis.10 
Although, the mechanism of endothelial damage is not clear. 
 
8. Thrombophilia:  
The contribution of thrombophilic states to the thrombosis in Philadelphia-negative MPN has 
been documented in some studies. A carrier state for FV Leiden has been associated with venous 
thromboembolism (VTE) relapse.25 High factor V levels, anti-phospholipid antibody (APLA)49 
and acquired activated protein C resistance (aAPCR)51, 52 are also independently associated with 
an increased risk of thrombosis.44  
 
9. Coagulation system activation:  
Probably due to a combination of the above-mentioned factors, there is activation of the 
coagulation system as a whole. This has been shown by increased serum thrombin-antithrombin 
complex, prothrombin fragment 1 + 2, and D-dimer in ET and PV.10  
 
10. Association between the JAK2V617F mutation and thrombosis in Philadelphia negative 
MPN 
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JAK2 (Janus kinase 2) is a cytoplasmic tyrosine kinase with a key role in signal transduction 
from multiple hemopoietic growth-factor receptors.7 The gene which encodes the JAK2 protein 
is present on chromosome 9p24. 
JAK2V617F mutation 
A clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) 
gene is seen in several patients with Philadelphia negative myeloproliferative diseases. The 
mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive 
tyrosine phosphorylation activity that promotes cytokine hypersensitivity.8  
The prevalence of JAK2 mutation is as given in table 17. 
 
Table 1: Prevalence of JAK2 positivity 
 JAK2 positive 
Polycythemia vera 97% 
Essential thrombocythemia 57% 
Idiopathic myelofibrosis 50% 
 
The expression of JAK2V617F in cytokine dependent cell lines confers cytokine independence. 
There is cytokine hypersensitivity too. These occur through the constitutive activation of STAT5, 
Akt and ERK-dependent pathways.59 This triggers terminal erythroid amplification in cells from 
patients with polycythemia vera.58  
JAK2-V617F stem cells show signs of senescence and exhaustion.67 JAK2-V617F has been 
reported to induce DNA damage, and has been shown to increase homologous recombination and 
genetic instability.68  
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JAK2 mutation and latent MPN 
The JAK2-V617F mutation is present even in patients who do not have overt features of MPN.  
Thus this mutation is able to diagnoses patients with latent MPN, most often ET. In 38% of 
patients with splanchnic vein thrombosis (SVT) the JAK2 mutation is detected even though they 
have normal/low blood cell counts. In these patients, polycythemia and thrombocytosis may be 
present. Overt clinical features of PV or ET are masked by hemodilution and/or hypersplenism in 
these patients, making the diagnosis of MPN difficult.4, 29   
 
JAK2 mutation and blast transformation 
JAK2 mutation has not been shown to be maintained in the blasts, after blast transformation.63  
 
Influence of the JAK2 mutation on thrombotic tendency 
JAK2 and hemostatic activation variables: 
Patients with ET with the JAK2 mutation have significantly lower levels of free protein S (PS) 
and higher levels of tissue factor (TF), soluble P-selectin,26, 28 soluble CD40 ligand (sCD40L), 
von Willebrand antigen (VWF:Ag), surface thrombomodulin (sTM) and plasma 
thrombomodulin10 than those with the wild-type allele.30  
Circulating platelet/PMN aggregates were significantly greater in the JAK2-mutation carriers 
than in the wild-type and controls.  
PMN surface activation and inflammatory markers (i.e., CD14, TF, CD11b, and leukocyte 
alkaline phosphatase [LAP]) are all significantly higher in ET versus control subjects, with CD14 
and LAP being the highest in the JAK2 mutation carriers.  
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Thus various biochemical markers of a prothrombotic state are elevated in JAK2 mutation 
carriers. 
 
Patients with ET wild-type, ET V617F, and PV have shown a rate of thrombosis of 1.4%, 2.1%, 
and 2.7%/patients/year, respectively. In PV this was found to progressively increase according to 
time of diagnosis. Actuarial probability of arterial and venous thrombosis in the first 5 years of 
diagnosis was roughly similar in the three groups. While in the subsequent periods, the curves of 
mutated ET patients diverged from wild-type, and after 10 to 15 years the ET-mutated arm 
approached PV. These findings may support the concept of a continuum between ET JAK2 
mutated and PV, not only in reference to the hematological phenotype, but also in terms of 
vascular events. 66  
A plausible explanation for these conflicting results may be that most of the studies are on 
patients with ET. These studies had a relatively small number of mutated patients ranging from 
38 to 165. Also fewer patients with ET are JAK2 mutation positive as compared to polycythemia 
vera. Compounding this issue is the fact the not all the patients which are studied will have 
thrombosis or bleeding. Thus these studies had a small study sample size with only about 10 to 
42 patients suffering from major cardiovascular events. 59  
 
Bleeding in Philadelphia negative MPN18 
A positive history of bleeding was present in 8.1% of patients of PV in the ECLAP trial.  
The factors associated with bleeding are: 
- Age 
- Disease duration 
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- Prior history of bleeding 
- High platelet counts (>1000 x 109/L)77   
 
Blast transformation 
The presence of JAK2V617F appears not to be a prerequisite for leukemic transformation of 
MPN, and additional genetic events seem to be required for full transformation. JAK2V617F in 
association with 9p copy number neutral-loss of heterozygosity (CNN-LOH) appear to have no 
impact on the time to MPN transformation. Nevertheless, the homozygous driver mutation in 
combination with additional newly acquired aberrations in terms of a second hit may have an 
implication on the clinical course of MPN-blast phase patients. Since, 
homozygous JAK2 mutation has been linked to an inferior outcome in MPN-blast crisis in 
comparison with patients with either heterozygous JAK2V617F or wild-type JAK2.64  
 
Patients who are JAK2 positive but do not fulfill criteria for MPN 
Some patients may fulfill criteria for MPN on follow-up. The presence of JAK2(V617F) 
mutation should been suggested a prothrombotic state for cerebral, coronary and peripheral 
microvascular disturbances and for splanchnic vein thrombosis but not for deep vein 
thrombosis.74    
 
Treatment 
The treatment of patients varied as per the diagnosis. 
Polycythemia vera 
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Patients of PV had usually been treated with venesection to maintain a hematocrit of 45%. 
Hydroxyurea was used if this target was not reached with regular venesection or in high risk 
patients. Other indications for Hydroxyurea were symptomatic or progressive splenomegaly, 
platelet counts >1500x109 /L and progressive leukocytosis. Risk was determined by the presence 
of a previous history of thrombosis or by age >60 years. Low-dose Aspirin was given to all 
patients. 
 
Essential thrombocythemia 
All patients were treated with Aspirin, except if the platelet counts were >1000x 109 /L, when 
this was first reduced with Hydroxyurea. All patients who were at a high risk of thrombosis are 
treated with Hydroxyurea.76  
 
Primary myelofibrosis 
PMF was treated with Hydroxyurea, or with Thalidomide with or without Prednisolone. 
Hydroxyurea was used for symptomatic splenomegaly and for those who had symptomatic 
thrombocytosis and/or leukocytosis. Splenomegaly and cytopenias also respond to Thalidomide 
with or without low-dose Prednisolone. Aspirin was given along with Thalidomide. 
Aspirin is often given to patients with MPN to mitigate the risk of thrombosis. Low-dose aspirin 
administered once daily is usually given but there is some data to suggest that this may be 
inadequate to fully suppress thromboxane production in ET, since accelerated platelet 
regeneration in most aspirin-treated ET patients may explain aspirin-persistent 
TXA2 biosynthesis through enhanced COX-2 activity and faster renewal of unacetylated COX-
1.70  
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Objectives and aims of study  
1. To study the clinical profile of patients with Philadelphia negative chronic 
myeloproliferative diseases.  
2. To assess the prevalence of thrombotic events in these disorders in our population. 
 
Hypotheses 
The phenotype of the classical Philadelphia negative chronic myeloproliferative disease 
in India is similar to that reported in the International literature. 
 
Inclusion Criteria (All) 
1. All the patients who have undergone testing for JAK2 mutation in Christian Medical 
College, Vellore. 
2. All of these patients who can be categorized in to a specific Philadelphia negative 
myeloproliferative neoplasm diagnostic category, as described in the ‘WHO 
Classification of Tumors of Hematopoietic and Lymphoid Tissues’, Fourth Edition. An 
outline of this has been mentioned in the chart. 
3. Patients who have been inadequately evaluated but nevertheless have some features of 
MPN and hence can be labeled as ‘probable MPN’. 
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WHO criteria for diagnosis of polycythemia vera, essential thrombocythemia and primary 
myelofibrosis 
 
Exclusion Criteria (Any) 
1. Patients who haven’t been evaluated adequately so as to be able to categorize them in to 
any specific diagnosis of Philadelphia negative myeloproliferative neoplasm. 
2. Philadelphia chromosome positivity by conventional cytogenetics, FISH or RT PCR. 
 
Study design 
1. A retrospective cross sectional study of patients who are diagnosed to have the classical 
Philadelphia-negative chronic myeloproliferative disease (polycythemia vera, essential 
thrombocytosis, idiopathic myelofibrosis) and probable MPN. From June 2009 the 
patient data was also followed prospectively till August 2010. 
2. The analysis included all the patients with these diagnoses, who were seen in the 
Department of Hematology of Christian Medical College, Vellore between January 2005 
and September 2010.  
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3. They were assessed for their clinical presentation, which included the history and clinical 
findings.  
4. Their laboratory features were documented with respect to the hematologic parameters, JAK2 
mutation status. 
 
Patients 
The database of patients who had undergone testing for JAK2 mutation was searched for 
identifying patients with MPN. Outpatient and inpatient records of these patients were accessed 
from the Medical Records Department. All efforts were taken to enroll as many patients as 
possible. Consecutive patients who had undergone testing for JAK2 mutation and for whom 
medical records were available were enrolled in the study to prevent any recruitment bias.  
The clinical features at presentation including the signs and symptoms were recorded. The details 
of the laboratory findings at diagnosis and on follow-up were noted too. If the patients had 
undergone initial evaluation at another medical facility, then the clinical findings and laboratory 
values recorded at that time were used for analysis. 
Thrombosis was defined any thrombotic event affecting the arterial circulation leading to 
decreased organ perfusion such as cerebral or coronary ischemia or occlusion of the venous 
circulation leading to deep vein, abdominal vein thrombosis, etc. Clinical symptoms of 
erythromelalgia, transient ischemic attack (TIA) and tingling or numbness of extremities, which 
are due to microvascular insufficiency were categorized as microvascular events. 
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Laboratory evaluation 
Patients had undergone a complete blood count on Beckman Coulter LH 750 cell counter. 
Peripheral blood smears were reviewed if the cell counter flagged for high or low values of 
hemoglobin, WBC or platelets or if immature WBCs were identified by the cell counter. 
Peripheral smears were stained by Leishman stain and a manual differential WBC count was 
done on 100 cells. Liver and renal function tests and lactate dehydrogenase (LDH) were tested 
on automated chemistry analyzers. Some patients with thrombosis had undergone evaluation for 
a prothrombotic condition. 
 
Bone Marrow Aspirate  
 Bone marrow was aspiration and core biopsy were done as part of diagnostic evaluation from 
the posterior superior iliac spine. The bone marrow aspirate smears were stained with May 
Grunwald Geimsa stain and a differential count was done on 500 nucleated cells. If immature 
cells were identified on the bone marrow aspirate smear then cytochemistry was performed using 
Sudan Black B and Periodic acid Schiff reagent stains. Flow cytometry for was done for 
abnormal cells if the bone marrow morphology and cytochemistry was not diagnostic. The bone 
marrow trephine was fixed in paraffin by the slow decalcification method. Staining was with 
hematoxylin and eosin (H&E) stain for general architecture and morphology and Gomori silver 
stain for reticulin. 
 
JAK2 mutation analysis 
The JAK2 mutation was detected with an allele specific PCR for detecting V617F mutation in 
Exon 14 of the Jak2 gene as follows: 7  
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9 ml of EDTA anti coagulated peripheral blood was collected and stored at 4C until DNA 
extraction. DNA was extracted using Phenol-Chloroform method and stored at 4C. 100ng of 
patients DNA was amplified in a 36-cycle PCR reaction at an annealing temperature of 58°C. 1 
micromolar concentration of a common reverse primer and 05 micromolar concentration of two 
forward primers will used as given below  
Reverse: 5-CTGAATAGTCCTACAGTGTTTTCAGTTTCA-3 
Forward (specific):   5-AGCATTTGGTTTTAAATTATGGAGTATATT-3                                    
Forward (internal control): 5-ATCTATAGTCATGCTGAAAGTAGGAGAAAG-3                    
The first forward primer is specific for the mutant allele and contains an intentional mismatch at 
the third nucleotide from the 3 prime end to improve specificity (giving a 203-bp product); the 
second amplifies a 364-bp product from both mutant and wild-type alleles and serves as an 
internal PCR control. The PCR products will then be run on a 3% agarose gel. Presence of the 
low molecular weight (203-bp) band indicates the mutation is carried by the patient; the high 
molecular weight (364-bp) band acts as an internal PCR control. 
 
Treatment 
Patients had been treated as per the outlines mentioned in the chart given below. 
 
Definitions 
Response criteria  
The responses to treatment for patients with PMF were graded as per the recommendations of the 
International working group80 and that for PV and ET as per the European LeukemiaNet 
consensus conference.81  
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Statistical analysis 
Descriptive statistics were calculated for all variables. Statistical analysis was performed using 
SPSS 16.0 software (SPSS,Chicago, IL). 
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RESULTS 
 
A total of 540 patients underwent testing for JAK2 mutation in CMC, Vellore from January 2005 
to September 2010. Charts, for review, were available for 477 patients. Out of these, an analysis 
was done on 227 patients as mentioned in figure 1.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow chart depicting the patient selection. 
 
Baseline Characteristics  
The most common diagnosis was polycythemia, either polycythemia vera or secondary 
erythrocytosis, 26.3% and 29% respectively. Details of the frequency of various diagnoses have 
been given in table 2. Patients with polycythemia vera, essential thrombocythemia and primary 
myelofibrosis, cellular phase of myelofibrosis, post PV and post ET myelofibrosis constituted the 
majority of patients. Patients with polycythemia who were JAK2 negative, with a high 
Total cases from 2005-2010 
(540) 
• Philadelphia positive (7) 
• Diagnosis not established (57) 
• Not MPN (125) 
• Eosinophilia (11) 
Charts available for review 
(477) 
MPN and probable MPNs analyzed 
(227) 
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erythropoietin level and whose bone marrow features were not suggestive of polycythemia vera, 
as per the WHO criteria, were classified as secondary polycythemia. Some patients had 
undergone JAK2 mutation analysis after having presented with abdominal vein thrombosis. A 
subset of these did not have any clinical or laboratory evidence of having a myeloproliferative 
neoplasm and these were categorized as patients with isolated abdominal vein thrombosis 
without any obvious underlying MPN. Patients with secondary polycythemia and those with 
abdominal vein thrombosis without any other evidence of MPN were not included in the further 
analysis since they did not fulfill the inclusion and exclusion criteria. A significant subset of 
patients had some clinical and laboratory evidence of a myeloproliferative neoplasm, but they 
had not undergone sufficient diagnostic evaluation to categorize them in to a specific type of 
MPN. These patients were included in the analysis as a ‘probable MPN’ group. 
 
Table 2: Frequency of diagnosis 
Diagnosis N Percent 
PV 96 26.3 
ET 31 8.5 
PMF 48 13.2 
Cellular phase of PMF 18 4.9 
Secondary polycythemia 106 29 
Abdominal vein thrombosis (AVT) 32 8.8 
Post ET MF 1 0.3 
Post PV MF 5 1.4 
Probable MPN 28 7.6 
 
From the 277 patients who were further analyzed, 179 (78.9%) were males and 48 (21.1%) were 
females (table 3A). There was a male predominance in all the diagnostic subsets, except in ET 
(table 3A). The mean age of diagnosis was 47.8 (±12.5) years, with the range being 10-75 years. 
The youngest patient was 10 years old and had ET.  
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The other baseline characteristics which could potentially contribute to an increased risk of 
thrombosis have been detailed in table 3B. A large proportion of patients with polycythemia 
were hypertensive, 44 (45.8%) and diabetic 18 (18.8%). 
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Table 3A: Age and sex frequencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3B: Other baseline characteristics                                 
 PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular phase  
of PMF 
n (%) 
Post 
ET MF 
n (%) 
Post 
PV MF 
n (%) 
Probable 
MPN 
n (%) 
General  
population % 
Hypertensive 44 (45.8) 6 (19.4) 10 (20.8) 3 (16.7) 0 (0) 2 (40) 14 (50) 4-45%107  
Diabetic 18 (18.8) 3 (9.7) 5 (10.4) 1 (5.6) 0 (0) 1 (20) 3 (10.7) 3-16%107  
Smoking 19 (19.8) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 10 (35.7) 10-45%107  
Alcohol 7 (7.3) 0 (0) 1 (2.1) 0 (0) 0 (0) 0 (0) 2 (7.1) 6-60%108, 109  
Dyslipidemia 9 (9.4) 1 (3.2) 0 (0) 1 (5.6) 0 (0) 0 (0) 2 (7.1) 14-39%107  
Chronic 
kidney 
disease 
2 (2.1) 1 (3.2) 2 (4.2) 0 (0) 0 (0) 0 (0) 0 (0) 0.8-1.4%110  
        
Diagnosis Age (years)  
Mean ± SD 
Sex 
Male n (%) Female n (%) 
Overall 47.8 ±12.5 179 (78.9) 48 (21.1) 
PV 48.68 ±11.44 83 (86.5) 13 (13.5) 
ET 41.55 ±13.57 16 (51.6) 15 (48.4) 
PMF 48.54 ±12.62 36 (75) 12 (25) 
Cellular phase of PMF 50.17 ±14.23 15 (83.3) 3 (16.7) 
Post ET MF 36 1 (100) 0 (0) 
Post PV MF 59.2 ±6.02 4 (80) 1 (20) 
Probable MPN 47.04 ±12.35 24 (85.7) 4 (14.3) 
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Duration of illness, and symptoms, clinical features, laboratory characteristics at diagnosis 
(table 4A and 4B) 
• Hepatomegaly was prominent in PMF median 2 (0-14) cm and post PV MF, median 3 (0-
4) cm. However, one patient of PV also had a liver enlargement of 17 cm below the 
costal margin. 
• Similarly, splenomegaly was prominent in PMF, median enlargement 10 (0-23) cm 
below the costal margin, cellular phase of PMF median 4.5 (0-20) cm and post-PV MF 
median 16 (1-22) cm. 
• As expected, hemoglobin (Hb) was highest in PV, mean 18.8 (±2.29) g/dl. The probable 
MPN group had an Hb of 18.14 (±3.5) g/dl. The lowest mean Hb was in PMF, mean 10.8 
(±3.6) g/dl. The lowest value of Hb was in a patient of PMF, 3.9 g/dl. 
• The highest median WBC count was in patients with post PV MF and cellular phase of 
MF, 40.9x103 /cmm (3.8-67.1) and 24.8 x103 /cmm (3.5-63.1), respectively. One patient 
of PMF had a WBC count of 316.4 x103 /cmm. 
• The highest median platelet counts were in ET (1087 x103 /cmm (597-2620)), cellular 
phase of MF (603.5 x103 /cmm (151-3193)) and in the one patient with post-ET MF 
(1184 x103 /cmm). Overall the highest platelet count was in a patient with PMF, 3457 
x103 /cmm. 
• The highest LDH values were in PMF (1584.5 (218-3798) U/l) and post-PV MF (1441.8 
(±707) U/l). 
• Erythropoietin levels in PV were 3.7 (1.56-29.6).  
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Salient points in presenting symptoms at diagnosis (table 5)  
• Several (n=72, 31.7%) of the patients, such as those with polycythemia (45.7%) and ET 
(35.5%) had been incidentally detected to have an MPN while being evaluated for an 
unrelated illness.  
• The most common clinical feature by which patients of PV, ET and probable MPN had 
presented to a doctor was thrombosis. 
•  Bleeding was present in 9 (4%) of patients.  
• Rubor and aquagenic pruritus was the presenting feature in very few patients with 
polycythemia.  
• Erythromelalgia was only present in 4 (1.8%) patients with PV and ET 
• Splenomegaly was the commonest presenting feature in both the cellular and fibrotic 
phase of PMF and was seen in about 30% of these patients. 
• Similarly, weight loss was the presenting feature in several patients with myelofibrosis, 
whether it was PMF, post ET or post PV MF. 
• Fever, Raynaud’s phenomenon, hyperviscosity, giddiness and tingling of extremities 
were rare presenting feature. 
• Anemia, as a presenting feature was only seen in PMF. 
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Table 4A: Duration of illness, and symptoms and clinical features at diagnosis (median (range)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4B: Laboratory characteristics at diagnosis 
 
Diagnosis Hb g/dl MCV ul WBC x103/cmm Platelets 
x103/cmm 
LDH U/l Erythropoietin 
 (mean±SD) median (range) Mean ±SD or median (range) median (range) 
PV 18.8±2.29 82.5±11.8 13.8 (4.8-49.9) 332.5 (12-1600) 658 ±287 3.7 (1.56-29.6) 
ET 12.5±2.14 83.4±10.3 13.6 (4.4-56) 1087 (597-2620) 574 ±182 6.3 
PMF 10.8±3.6 85.1 ±9.9 12.8 (2.6-316.4) 292 (5-3457) 1584.5 (218-3798) NA 
Cellular 
phase of 
PMF 
13.1±3 84.5±12.4 24.8 (3.5-63.1) 603.5 (151-3193) 954.6±485 24.8 
Post ET MF 11.2 107.4 6.8 1184 231 NA 
Post PV MF 14.9±2.5 73.4±10.6 40.9 (3.8-67.1) 328 (108-752) 1441.8±707 3.34 
Probable 
MPN 
18.14±3.5 87.1±15.7 11 (1.8-38.8) 309.5 (43-1228) 467 (235-1557) 8.45 (4-18.5) 
 
Legend: Hb: hemoglobin, MCV: mean corpuscular volume, WBC: white blood cells, LDH: lactate dehydrogenase
Diagnosis Duration of symptoms (weeks) Liver (cm) Spleen (cm) 
PV 2 (0-520) 0 (0-17) 0 (0-16) 
ET 6 (0-196) 0 (0-4) 0 (0-18) 
PMF 8 (0-312) 2 (0-14) 10 (0-23) 
Cellular phase of PMF 4 (0-104) 0 (0-7) 4.5 (0-20) 
Post ET MF 32 0 0 
Post PV MF 32 (12-156) 3 (0-4) 16 (1-22) 
Probable MPN 3.5 (0-176) 0 (0-7) 0 (0-30) 
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Table 5: Symptoms at diagnosis 
 
Table 6: Gout and pruritus during the course of illness 
 
Clinical 
manifestation 
PV  
n (%) 
ET  
n (%) 
PMF  
n (%) 
Cellular phase of  
PMF  
n (%) 
Post  
ET MF  
n (%) 
Post  
PV MF  
n (%) 
Probable MPN  
n (%) 
Gout 1 (1) 0 (0) 1 (2.1) 1 (5.6) 1 (100) 1 (20) 1 (3.6) 
Pruritus 9 (9.4) 1 (3.2) 2 (4.2) 1 (5.6) 0 (0) 1 (20) 3 (10.7) 
 
 
 
Clinical manifestation PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular phase 
of PMF 
n (%) 
Post ET MF 
n (%) 
Post PV 
MF 
n(%) 
Probable MPN 
n (%) 
No symptoms 43 (45.7) 11 (35.5) 6 (13) 3 (16.7) 0 (0) 1 (20) 8 (29.6) 
Thrombosis 23 (24.5) 8 (25.8) 0 (0) 3 (16.7) 0 (0) 1 (20) 8 (29.6) 
Bleeding 3 (3.2) 0 (0) 1 (2.2) 2 (11.1) 0 (0) 0 (0) 3 (11.1) 
Rubor 3 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.7) 
Splenomegaly 4 (4.3) 1 (3.2) 14 (30.4) 6 (33.3) 0 (0) 0 (0) 1 (3.7) 
Aquagenic pruritus 2 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Weight loss 1 (1.1) 0 (0) 7 (15.2) 2 (11.1) 1 (100) 2 (40) 1 (3.7) 
Erythromelalgia 1 (1.1) 3 (9.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Headache 5 (5.3) 4 (12.9) 1 (2.2) 1 (5.6) 1 (20) (0) 0 (0) 
Fever 0 (0) 1 (3.2) 2 (4.3) 1 (5.6) 0 (0) 0 (0) 0 (0) 
Raynaud’s phenomenon 1 (1.1) 2 (6.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Anemia 0 (0) 0 (0) 7 (15.2) 0 (0) 0 (0) 0 (0) 0 (0) 
Tingling of extremities 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (7.4) 
Generalized weakness 6 (6.4) 0 (0) 7 (15.2) 0 (0) 0 (0) 0 (0) 3 (11.1) 
Hyperviscosity 0 (0) 0 (0) 1 (2.2) 0 (0) 0 (0) 0 (0) 0 (0) 
Giddiness  1 (1.1) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
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Prevalence of gout and pruritus during the course of illness (table 6) 
Gout: Present in 6 (2.6 %) of patients, mostly in those with myelofibrosis, table 6. 
Pruritus: Was present in 17 (7.5%) of patients and mostly in those with polycythemia (9.4%), 
table 6. 
 
Vascular events during the course of illness  
Arterial (table 7): Arterial thromboses were were most frequent in the probable MPN group 
where 10 (35.77%) of patients had thrombosis. This was followed by PV and ET where 29 
(29.9%) and 8 (25.8) of patients had suffered some thrombotic event, respectively. The details of 
these have been described subsequently. 
1. Microvascular events (fig. 2): Erythromelalgia and tingling and numbness of the 
extremities were the most frequent microvascular event and were seen in only 5 (2.2%) 
and 1 (0.4%) of patients respectively. 
Visual disturbances suggestive of amaurosis fugax, were present in isolated patients of 
PV and ET. 
Three (3.1%) patients of PV had Raynaud’s phenomenon. 
2. Macrovascular thrombosis (fig. 3) 
Macrovascular thrombosis was most frequent in PV seen in 22 (22.8%) and in the 
probable MPN group where 8 (28.6%) of patients had such events. 
Thrombotic events of the central nervous system (CNS), including stroke and TIA, were 
seen with the maximum frequency in PV, 17 (17.7%). 
7 (3.1%) of patients had coronary arterial thrombotic events. 
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Gangrene of the extremities was seen in 5 (2.2%) patients. This included brachial artery 
occlusion in 1 (0.4%), toe gangrene in 3 (1.3%) and lower limb gangrene, not otherwise 
specified in 1 (0.4%) of patients. 
 
3. Recurrent: A second episode of stroke and transient ischemic attack was present in one 
patient of PV each. 
 
Venous thrombosis (table 8 and figure 4) 
Venous thrombosis was most frequent in ET since 7 (22.6%) of patients had such events. 
The commonest site was intraabdominal veins in 16 (5.8%) of patients as the site of first 
thrombosis. In 1 (0.4%) patient an abdominal vein thrombosis (AVT) was the second site of 
thrombosis. This patient had developed the first episode of thrombosis in the upper limb which 
was followed by abdominal vein thrombosis. 
The other sites of first thrombosis were cortical venous sinus thrombosis (CVT) in 5 (2.2%) and 
lower limb deep vein thrombosis (DVT) in 3 (1.3%) each. One (0.4%) patient had been 
diagnosed to have upper limb deep venous thrombosis. 
Recurrent venous thrombosis was seen in 2 (0.8%) of patients. One patient had two episodes of 
lower limb DVT and the other had AVT as described above.  
 
Multiple thromboses (table 9) 
Overall, a total of 7 (3.1%) of patients had developed multiple thrombosis. These are detailed in 
table 9. Six of these seven patients had polycythemia. One patient with multiple thromboses had 
ET. 
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Evaluation for a prothrombotic work-up (table 10) 
Amongst all the patients who had suffered a thrombotic event, testing for a prothrombotic 
condition was performed in 8 patients and an abnormality was detected in 4 patients. Their 
details have been mentioned in table 10. 
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Figure 2: Microvascular events 
 
 
 
Figure 3: Total macrovascular arterial events 
 
Legend: TIA: transient ischemic attack 
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Figure 4: Total venous thrombosis  
 
Legend: CVT: cortical venous thrombosis, DVT: deep vein thrombosis, AVT: abdominal vein 
thrombosis 
 
 
Figure 5: Frequencies of bleeding events 
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Table 7: Arterial vascular events during the course of illness 
Vascular events PV  
n (%) 
ET  
n (%) 
PMF  
n (%) 
Cellular phase  
of PMF n (%) 
Post ET  
MF n (%) 
Post PV 
MF n (%) 
Probable  
MPN n (%) 
Microvascular events 
Visual disturbances 1 (1) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Tingling and 
numbness of 
extremities 
0 (0) 0 (0) 1 (2.1) 0 (0) 0 (0) 0 (0) 1 (3.57) 
Raynaud’s 
phenomenon 
3 (3.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Erythromelalgia 1 (1) 1 (3.2) 1 (2.1) 0 (0) 0 (0) 1 (20) 1 (3.6) 
Total 5 (5.1) 2 (6.4) 2 (4.2) 0 (0) 0 (0) 1 (20) 2 (7.17) 
Macrovascular thrombosis 1st event 
Stroke 15 (15.6) 2 (6.5) 0 (0) 1 (5.6) 0 (0) 0 (0) 5 (17.9) 
TIA (transient 
ischemic attack) 
2 (2.1) 1 (3.2) 0 (0) 1 (5.6) 0 (0) 0 (0) 0 (0) 
Acute Myocardial 
Infarction 
2 (2.1) 2 (6.5) 0 (0) 0 (0) 1 (100) 0 (0) 2 (7.1)  
Brachial artery 
thrombosis 
1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Toe gangrene 1 (1) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 
Lower limb 
gangrene 
1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 22 (22.8) 6 (19.4) 0 (0) 2 (11.2) 1 (100) 0 (0) 8 (28.6) 
Macrovascular thromboses 2nd event 
Stroke 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
TIA 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Overall total 29 (29.9) 8 (25.8) 2 (4.2) 2 (11.2) 1 (100) 1 (20) 10(35.77) 
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Table 8: Venous thrombosis 
 
Table 9: Multiple thromboses 
Patient serial 
number 
Microvascular 
thrombosis 
Macrovascular 
thrombosis 
Venous 
thrombosis 
Diagnosis 
70 - Stroke, TIA - PV 
88 - TIA AVT ET 
91 Raynaud’s 
phenomenon 
- Upper DVT, 
AVT 
PV 
110 Erythromelalgia Toe gangrene - PV 
140 - Stroke, stroke 
(2nd episode) 
CVT PV 
156 Raynaud’s 
phenomenon 
- AVT PV 
317 Raynaud’s 
phenomenon 
Stroke - PV 
 
Table 10: Prothrombotic risk factors 
Serial number Diagnosis Sites of thrombosis Prothrombotic risk 
factor 
11 Probable MPN Lower DVT High factor VIII 
20 Probable MPN CVT High factor VIII, 
lupus anticoagulant 
34 Probable MPN AVT High factor VIII 
284 Cellular phase of 
PMF 
Stroke lupus anticoagulant 
 
Legend for tables 8-10:  CVT: cortical venous thrombosis, DVT: deep vein thrombosis, AVT: 
abdominal vein thrombosis, TIA: transient ischemic attack 
 
 
 
 
Thrombosis Overall 
n (%) 
PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular  
phase of  
PMF n (%) 
Post ET  
MF n (%) 
Post PV  
MF n (%) 
Probable  
MPN n (%) 
CVT 5 (1.8) 2 (2.1) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 2 (7.1) 
Upper DVT 1 (0.36) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Lower DVT 3 (1.1) 2 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 
AVT 16 (5.8) 7 (7.3) 6 (19.4) 0 (0) 1 (5.6) 0 (0) 1 (20) 1 (3.6) 
Total 25 (9) 12 (12.5) 7 (22.6) 0 (0) 1 (5.6) 0 (0) 1 (20) 4 (14.3) 
Recurrent thrombosis 
Lower DVT 1 (0.36) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
AVT 1 (0.36) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 2 (0.72) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
50 
 
Bleeding (table 11 and figure 5) 
The major sites of bleeding were gastrointestinal (GI), genitourinary (GU), respiratory and 
cutaneous. One patient each had bleeding from the bone marrow biopsy site and intracranial 
hemorrhage. Similarly, one patient had presented with left knee hemarthrosis of unknown 
etiology and was diagnosed to have cellular phase of PMF. 
GI hemorrhage was the most common site of bleeding and was seen in 14 (6.1%) of patients. 
This was most frequent in the cellular phase of PMF 3 (16.7%) and ET 4 (12.9) patients.  
Genitourinary hemorrhage was seen in one patient of polycythemia and in one patient of 
probable MPN. 
Similarly, occasional patients of PV and ET had epistaxis and one patient of PMF had 
hemoptysis whose anatomic cause could not be determined. 
Cutaneous bleeding in the form of ecchymosis was also present in isolated patients of ET and 
PMF. 
 
Leukemic transformation (table 12) 
In the current analysis 5 (2.2%) patients underwent leukemic transformation. This occurred in 1 
(3.2%) of patient with ET and 4 (8.3%) patients with PMF. The patient of ET developed acute 
myeloid leukemia 367 days after being diagnosed with ET.  
Amongst the 4 patients with PMF who had undergone leukemic transformation the median time 
from diagnosis of PMF to leukemic transformation was 52 weeks (range 33-365). 
None of the patients underwent definitive treatment for leukemia and was managed with 
palliative intent and subsequently expired. 
51 
 
Table 11: Bleeding 
Site of bleeding PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular phase of  
PMF 
n (%) 
Post 
ET MF
n (%) 
Post 
PV MF 
n (%) 
Probable MPN 
n (%) 
Gastrointestinal (GI) 
Gum 0 (0) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 
Varices 1 (1) 1 (3.2) 1 (2.1) 2 (11.1) 0 (0) 0 (0) 0 (0) 
Hemorrhoids 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
GI unspecified 1 (1) 2 (6.5) 1 (2.1) 1 (5.6) 0 (0) 0 (0) 1 (3.6) 
Total 3 (3) 4 (12.9) 2 (4.2) 3 (16.7) 0 (0) 0 (0) 2 (7.2) 
Genitourinary (GU) 
Hematuria 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 
GU unspecified 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 
Respiratory 
Epistaxis 2 (2.1) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Hemoptysis 0 (0) 0 (0) 1 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 2 (2.1) 1 (3.2) 1 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 
Miscellaneous 
Ecchymosis 0 (0) 1 (3.2) 1 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 
Bone marrow site bleeding 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Intracranial bleeding 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Hemarthrosis 0 (0) 0 (0) 0 (0) 1 (5.6) 0 (0) 0 (0) 0 (0) 
Overall total 8 (8.33) 6 (19.35) 4 (8.33) 4(22.22) 0 (0) 0 (0) 3 (10.71) 
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Table 12: Details of patients who underwent leukemic transformation 
 
 
Table 13: Details of patients who progressed to myelofibrosis 
Serial number Diagnosis Weeks to leukemic 
transformation (from diagnosis) 
Successive treatments received 
prior to development of leukemia 
96 PV 506 • Venesection 
• Hydroxyurea 
127 Post PV MF NA • Venesection 
• Hydroxyurea 
151 PV NA • Hydroxyurea 
• Thalidomide with 
Prednisolone 
242 PV 24 • Venesection 
335 PV 1383 • 32Phosphorus 
• Hydroxyurea 
• Thalidomide with 
Prednisolone 
339 Post PV MF 112 • Venesection 
• Hydroxyurea 
• Thalidomide with 
Prednisolone 
361 PV 537 • Venesection 
• Hydroxyurea 
 
Table 14: JAK2 positivity 
Diagnosis JAK2 positive n (%) 
PV 64 (66.7) 
ET 18 (58.1) 
PMF 23 (47.9) 
Cellular phase of PMF 11 (61.1) 
Post-ET MF 1 (100) 
Post-PV MF 5 (100) 
Probable MPN 12 (42.9) 
Total 134 (48.4) 
 
 
 
 
Serial  
number 
Diagnosis Weeks to leukemic 
transformation  
(from diagnosis) 
Successive treatments received  
prior to development  
of leukemia 
Marrow blasts 
at initial 
diagnosis of 
ET/PMF 
Lille’s score 
at diagnosis 
23 ET 52 • Hydroxyurea 8 - 
172 PMF 130 • Hydroxyurea 
• Interferon alpha 
15 0 
199 PMF 51 • Thalidomide <5 1 
290 PMF 33 • Thalidomide <5 1 
366 PMF 365 • Hydroxyurea 
• Thalidomide with Prednisolone 
10 0 
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Progression to myelofibrosis, table 13 
 
A total of 7 (7.3%) patients of PV had progression to myelofibrosis and the time for 
documentation of progression from the time of diagnosis of PV was known in 5 patients. 
This ranged from 24-1383 weeks with a median of 537 weeks. Two of these patients had 
been diagnosed outside to have PV and when they came for review to us they had 
developed progression to myelofibrosis, hence these patients were labeled as post-PV 
MF. 
 
JAK2 positivity (table 14) 
JAK2 mutation was positive in 134 (59%) patients, overall. The highest rate of positivity 
was in PV, 64 (66.7%). All the patients of post-PV and post-ET MF was JAK2 positive. 
 
Treatment details 
These have been described as per the sequential treatments received by patients has been 
detailed in table 24. 
 
First treatment (tables 15 and 16) 
• 32.3% of PV, 80.6% of ET and 83.3% of cellular PMF had been treated with 
hydroxyurea initially. 
• 63.5% of PV received venesection as first line of management. 
• Only one (1%) patient of PV had been treated with 32Phosphorus. 
• Single agent thalidomide or prednisolone was used in isolated patients of PMF 
while thalidomide with prednisolone was used in 31.2% of PMF and 5.6%of 
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cellular PMF patients. Busulfan, splenectomy and splenic irradiation had been 
given to one patient each of PMF. 
• Amongst all the disease groups, whatever treatment was given, 35-80% of 
patients had achieved a partial remission and clinical improvement in MF. 
 
Second treatment (table 17 and 18) 
• Hydroxyurea in 19% and venesection in 25% were the second line treatments for 
PV. 
• For patients with PMF hydroxyurea and thalidomide with prednisolone were used 
in 8.3% of patients each.  
• Similar to the first line of treatment, in almost all the disease groups, whatever 
treatment was given, 15-80% of patients had achieved a partial remission of stable 
disease and clinical improvement in MF.  
 
Third and fourth treatments (tables 19-22) 
• These were required in very few patients. 
 
Aspirin and oral anticoagulants (table 23) 
• Aspirin was used in about 50% of patients. 
 
 
 
 
 
 
 
Table 15: First treatment details 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16: Response to first treatment 
Response 1 PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular  
phase of PMF n (%) 
Post ET MF  
n (%) 
Post PV MF  
n (%) 
Probable MPN 
n (%) 
CHCR 23 (24.2%) 4 (14.3%) 1 (2.2%) 2 (12.5%) 0 (0%) 1 (20%) 7 (30.4%) 
CR for PMF NA NA 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
PR 68 (71.6%) 21 (75%) 16 (35.6%) 9 (56.2%) 1 (100%) 4 (80%) 14 (60.9%) 
PD NA NA 6 (13.3%) 1 (6.2%) 0 (0%) 0 (0%) 0 (0%) 
SD NA NA 14 (31.1%) 1 (6.2%) 0 (0%) 0 (0%) 0 (0%) 
NR 0 (0%) 3 (10.7%) 2 (4.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Not known 5 (5.2%) 0 (0%) 6 (13.3%) 3 (18.8%) 0 (0%) 0 (0%) 2 (8.7%) 
Legend: CHCR: clinic-hematologic complete remission, for MF this is equivalent to PR by IWG criteria, CR: complete remission, 
PR: partial remission and is equivalent to clinical improvement (CI) for MF by IWG criteria, PD: progressive disease, SD: stable 
disease and NR: no response.
Treatment 1 PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular  
phase of 
PMF n (%) 
Post  
ET MF 
n (%) 
Post  
PV MF 
n (%) 
Probable 
MPN 
n (%) 
None 3 (3.1%) 4 (12.9%) 4 (8.3%) 2 (11.1%) 0 (0%) 0 (0%) 5 (17.9%) 
Hydroxyurea 31 (32.3%) 25 (80.6%) 22 (45.8%) 15 (83.3%) 1 (100%) 2 (40%) 11 (39.3%) 
Venesection 61 (63.5%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 3 (60%) 12 (42.9%) 
Thalidomide 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Prednisolone 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Thalidomide + Prednisolone 0 (0%) 0 (0%) 15 (31.2%) 1 (5.6%) 0 (0%) 0 (0%) 0 (0%) 
Danazol 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
32Phosphorus 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Busulfan 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Splenectomy 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Splenic Irradiation 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Transfusions 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Stop smoking 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Anagrelide + Hydroxyurea 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Table 17: Second treatment details 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: SCT: stem cell transplantation 
 
Table 18: Response to second treatment 
Response 2 PV  
n (%) 
ET 
 n (%) 
PMF  
n (%) 
Cellular  
phase  
of PMF 
 n (%) 
Post  
PV MF 
n (%) 
Probable 
MPN 
n (%) 
CHCR 11 (26.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (50%) 
CR 1 (2.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
PR 28 (66.7%) 0 (0%) 2 (15.4%) 2 (100%) 4 (80%) 4 (50%) 
PD 0 (0%) 1 (50%) 2 (15.4%) 0 (0%) 0 (0%) 0 (0%) 
SD 1 (2.4%) 0 (0%) 4 (30.8%) 0 (0%) 0 (0%) 0 (0%) 
NR 0 (0%) 1 (50%) 1 (7.7%) 0 (0%) 0 (0%) 0 (0%) 
Not known 1 (2.4%) 0 (0%) 4 (30.8%) 0 (0%) 1 (20%) 0 (0%) 
 
Table 19:  Third treatment details 
Treatment 3 PV n (%) PMF n (%) Post PV MF n (%) Probable MPN n (%) 
Hydroxyurea 1 (1.1%) 1 (2.1%) 2 (40%) 0 (0%) 
Thalidomide +Prednisolone 1 (1.1%) 3 (6.3%) 1 (20%) 0 (0%) 
Interferon alpha 0 (0%) 1 (2.1%) 0 (0%) 1 (3.6%) 
Erythropoietin 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 
 
Table 20: Response to third treatment 
Response 3 PV n (%) PMF n (%) Post PV MF n (%) Probable MPN n (%) 
CHCR 0 (0%) 0 (0%) 1 (33.3%) 0 (0%)
PR 2 (100%) 1 (16.7%) 1 (33.3%) 1 (100%) 
PD 0 (0%) 2 (33.3%) 1 (33.3%) 0 (0%)
SD 0 (0%) 1 (16.7%) 0 (0%) 0 (0%)
NR 0 (0%) 2 (33.3%) 0 (0%) 0 (0%)
Legend for table 18 and 20: CHCR: clinic-hematologic complete remission, for MF this 
is equivalent to PR by IWG criteria, CR: complete remission, PR: partial remission and is 
equivalent to clinical improvement (CI) for MF by IWG criteria, PD: progressive disease, 
SD: stable disease and NR: no response. 
 
Treatment 2 PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular  
phase  
of PMF 
n (%) 
Post  
PV MF 
n (%) 
Probable 
MPN 
n (%) 
Hydroxyurea 18 (19%) 0 (0%) 4 (8.3%) 1 (5.6 %) 2 (40%) 2 (7.1%) 
Venesection 24 (25 %) 0 (0%) 0 (0%) 0 (0%) 1 (20%) 6 (21.4%) 
Thalidomide 0 (0%) 0 (0%) 2 (4.2%) 1 (5.6%) 0 (0%) 0 (0%) 
Prednisolone 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Thalidomide 
+Prednisolone 
0 (0%) 0 (0%) 4 (8.3%) 0 (0%) 1 (20%) 0 (0%) 
Lenalidomide 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 
SCT 0 (0%) 0 (0%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 
32Phosphorus 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
6Mercaptopurine 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (20%) 0 (0%) 
Transfusions 0 (0%) 1 (3.2%) 1 (2.1%) 0 (0%) 0 (0%) 0 (0%) 
Stop smoking 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
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Table 21: Fourth treatment details 
Treatment 4 PV n (%) PMF n (%) 
Hydroxyurea 0 (0%) 1 (2.1%) 
Thalidomide +Prednisolone 1 (1%) 0 (0%) 
Stem cell transplant (%) 1 (2.1%) 
Daflazacort (%) 1 (2.1%) 
 
 
Table 22: Response to fourth treatment 
Response 4 PVn (%) PMF n (%) 
Partial response 1 (100%) 1 (33.3%) 
Progressive disease 0 (0%) 1 (33.3%) 
Not known 0 (0%) 1 (33.3%) 
 
 
Table 23: Patients receiving Aspirin and oral anticoagulants 
 PV 
n (%) 
ET 
n (%) 
PMF 
n (%) 
Cellular 
phase  
of PMF 
n (%) 
Post  
ET MF 
n (%) 
Post  
PV MF 
n (%) 
Probable 
MPN 
n (%) 
Total 
n (%) 
Aspirin 63 (65.6%) 15 (48.4%) 23 (47.9%) 9 (50%) 1 (100%) 3 (60%) 13 (46.4%) 176 (48.2%) 
Oral 
anticoagulants 
8 (8.3%) 5 (16.1%) 0 (0%) 1 (5.6%) 0 (0%) 0 (0%) 3 (10.7%) 53 (14.5%) 
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DISCUSSION 
 
The myeloproliferative neoplasms are a heterogeneous group of diseases. There is 
minimal data from India regarding the clinical profile and treatment outcome in these 
disorders.  
Diagnostic subsets 
During the analysis of 227 patients we found that polycythemia was the commonest 
MPN. This was followed by PMF and ET which were less frequent. There were several 
patients who had some clinical features of MPN but who had not undergone complete 
evaluation to satisfy all the WHO diagnostic criteria. These could not be classified in to 
any one diagnostic subset and hence were grouped as probable MPN.  
 
Demographic data 
The mean age of PV, ET and PMF was about one decade less than what has been 
reported (table 3A and 25).79 The youngest patient was 10 years old and had ET.  
 
Table 25: Age distribution among MPNs 
 Reported79 Our study 
PV 60 years 48.68 (±11.44) 
ET 6th-7th decade 41.55 (±13.57) 
PMF 50-60 years 48.54 (±12.62) 
 
Along with this there was a significant male preponderance in the PV and PMF group 
(table 3A), although the MPNs have been reported to have an almost equal sex 
distribution.79 This discrepancy may be due to lesser availability of medical attention to 
women in India.90, 91 Compared to the other disease subsets, a large proportion of patients 
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with polycythemia were hypertensive, 44 (45.8%) and diabetic, 18 (18.8%), (table 3B). 
This also seems to be at least slightly more than what is prevalent in the population, 
although population estimates are heterogeneous and depend on the age group studied. 
The increased prevalence of hypertension with higher hematocrit is probably related to 
increased blood viscosity and has been shown to contribute to cardiovascular disease 
risk.92-95 19.8% of patients with PV were smokers. 
 
Duration of illness, and symptoms, clinical features, laboratory characteristics at 
diagnosis (table 4, 5 and 6) 
The duration of symptoms prior to seeking medical attention was varying and was 
longest in post ET and PV PMF (32 weeks). Several patients, such as those with primary 
(45.7%) and ET (35.5%) had been incidentally detected to have an MPN while being 
evaluated for an unrelated illness. This was much higher than what was published by 
Landolfi, et al who had 16% of patients who had been incidentally detected but these had 
been diagnosed using the Polycythemia Vera Study Group protocol.97 For ET, however, 
incidental diagnosis has been reported in about 50% of patients.98 Overall, the most 
common clinical feature by which patients had presented to a doctor was thrombosis. 
This has been reported earlier, such that in PV up to 2/3rd of the patients have had a 
thrombotic event before or during presentation with PV.5  
The second most common presenting manifestation in these patients was splenomegaly. 
However, this was the commonest presenting feature in both the cellular and fibrotic 
phase of PMF and was seen in about 30% of these patients. 
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Bleeding was the presenting symptom in a few patients, especially in PMF (13.3%) 
similar to what has been described by Varki, et al (20%).99  Rubor and aquagenic pruritus 
was the presenting feature in very few patients with either polycythemia. In the series by 
Seigel, et al, aquagenic pruritus had led to the diagnosis of PV in 4% of patients.101 
Pruritus was present in 27 (11.9%) of patients and mostly in those with polycythemia 
(9.4%), table 6. This was much lower than what has been reported (50%).103 The lower 
prevalence of pruritus in our series may be due to the retrospective nature of the analysis, 
due to recall bias.  
Erythromelalgia was infrequent and was present in only 4 (1.8%) patients with PV and 
ET, concordant with the published literature.100 Weight loss was the presenting feature in 
some patients with myelofibrosis, whether it was PMF (15.2%), post ET or post PV MF. 
This was similar to what was described by Silverstein.102 Fever, Raynaud’s phenomenon, 
hyperviscosity, giddiness and tingling of extremities were rare presenting feature. 
Similarly, anemia, as a presenting feature was only seen in PMF. Gout was present in 6 
(2.6%) of patients, mostly in those with myelofibrosis 4 (5.6%), table 6 as described by 
Silverstein.102 
Hepatomegaly was prominent in PMF median 2 (0-14) cm and post PV MF, median 3 (0-
4) cm. However, one patient of PV also had a liver enlargement of 17 cm below the 
costal margin. Similarly, splenomegaly was prominent in PMF, with a median 
enlargement of 10 (0-23) cm below the costal margin, cellular phase of PMF median 4.5 
(0-20) cm and post-PV MF median 16 (1-22) cm. 
As expected, hemoglobin (Hb) was highest in PV, mean 18.8 (±2.29) g/dl. The probable 
MPN group had an Hb of 18.14 ±3.5 g/dl. The lowest mean Hb was in PMF, mean 
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10.8±3.6 g/dl. The lowest value of Hb was in a patient of PMF, 3.9 g/dl. The highest 
median WBC count was in patients with post PV MF and cellular phase of MF, 40.9x103 
/cmm (3.8-67.1) and 24.8 x103 /cmm (3.5-63.1), respectively. One patient of PMF had a 
WBC count of 316.4 x103 /cmm. The highest median platelet counts were in ET (1087 
x103 /cmm (597-2620)), cellular phase of MF (603.5 x103 /cmm (151-3193)) and in the 
one patient with post-ET MF (1184 x103 /cmm). Overall the highest platelet count was in 
a patient with PMF, 3457 x103 /cmm.  
The highest LDH values were in PMF (1584.5 (218-3798) U/l) and post-PV MF (1441.8 
(±707) U/l). A serum LDH above the normal range has been shown to occur in 89% of 
patients with PMF and a serum LDH of twice the upper limit of normal was identified as 
a reasonable discriminator of PMF from ET/PV, with a sensitivity of 55% and 
specificity of 94%.96  Erythropoietin levels in PV were 3.7 (1.56-29.6). Thus these were 
high in some patients who otherwise were fitting in to the WHO criteria for the diagnosis 
of PV. These observations are consistent with data which has been published earlier.104  
  
Thrombosis during the course of illness  
Arterial (table 7): Arterial thromboses were frequent and these were most frequent in 
the probable MPN group where 10 (35.77%) of patients had thrombosis. This was 
followed by PV and ET where 29 (29.9%) and 8 (25.8) of patients had suffered some 
thrombotic event, respectively. The details of these have been described subsequently. 
1. Microvascular events 
Erythromelalgia and tingling and numbness of the extremities were the most frequent 
microvascular event and were seen in only 5 (2.2 %) and 2 (0.9%) patients respectively. 
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Visual disturbances suggestive of amaurosis fugax, were present in isolated patients of 
PV and ET. Three (3.1%) patients of PV had Raynaud’s phenomenon. 
2. Macrovascular thrombosis 
Macrovascular thrombosis was most frequent in PV seen in 22 (22.8%) and in the 
probable MPN group where 8 (28.6%) of patients had such events. Thrombotic events of 
the central nervous system (CNS), including stroke and TIA, were seen with the 
maximum frequency in PV, 17 (17.7%). Gangrene of the extremities was seen in 4 
(1.8%) patients. This included brachial artery occlusion in 1 (0.4%), toe gangrene in 3 
(1.3%) and lower limb gangrene, not otherwise specified in 1 (0.4%) of patients. The 
prevalence of arterial thrombosis and the observation that the central nervous system was 
the commonest site of thrombosis is consistent with earlier publications.104  
3. Recurrent arterial thromboses 
A second episode of stroke and transient ischemic attack was present in one patient of PV 
each. 
 
Venous thrombosis (table 8) 
Venous thrombosis was most frequent in ET since 7 (22.6%) of patients had such events. 
The commonest site was intraabdominal veins in 16 (7%) of patients as the site of first 
thrombosis. In 1 (0.4%) patient an abdominal vein thrombosis (AVT) was the second site 
of thrombosis. This patient had developed the first episode of thrombosis in the upper 
limb which was followed by abdominal vein thrombosis. The other sites of first 
thrombosis were cortical venous sinus thrombosis (CVT) in 5 (2.2 %) and lower limb 
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deep vein thrombosis (DVT) in 3 (0.88%) each. One (0.4%) patient had been diagnosed 
to have upper limb deep venous thrombosis.  
Recurrent venous thrombosis was seen in 2 (0.8%) of patients. One patient had two 
episodes of lower limb DVT and the other had AVT as described above. Similar to 
arterial thrombosis, the prevalence of venous thrombosis is also consistent with what has 
been published earlier.104  
 
Multiple thromboses (table 9) 
Overall, a total of 7 (3.1%) of patients had developed multiple thrombosis. These are 
detailed in table 9. Six of these seven patients had polycythemia. One patient with 
multiple thromboses had ET. 
 
Evaluation for a prothrombotic work-up (table 10) 
Amongst all the patients who had suffered a thrombotic event, an evaluation for a 
prothrombotic condition had been done for 8 patients, although a positive finding was 
present only in 4 patients. Their details have been mentioned in table 10. 
 
Bleeding (table 11) 
The major sites of bleeding were gastrointestinal (GI), genitourinary (GU), respiratory 
and cutaneous. One patient each had bleeding from the bone marrow biopsy site and 
intracranial hemorrhage. Similarly, one patient had presented with left knee hemarthrosis 
of unknown etiology and was diagnosed to have cellular phase of PMF. GI hemorrhage 
was the most common site of bleeding and was seen in 14 (6.2%) of patients. This was 
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most frequent in the cellular phase of PMF 3 (16.7%) and ET 4 (12.9) patients. 
Genitourinary hemorrhage was seen in one patient of polycythemia and in one patient of 
probable MPN. Similarly, occasional patients of PV and ET had epistaxis and one patient 
of PMF had hemoptysis whose anatomic cause could not be determined. Cutaneous 
bleeding in the form of ecchymosis was also present in isolated patients of ET and PMF. 
These sites and frequencies of bleeding are similar to previously published data.104  
 
Leukemic transformation (table 12) 
In the current analysis 5 (2.2%) patients underwent leukemic transformation. This 
occurred in 1 (3.2%) of patient with ET and 4 (8.3%) patients with PMF. The patient of 
ET developed acute myeloid leukemia 367 days after being diagnosed with ET. Amongst 
the 4 patients with PMF who had undergone leukemic transformation the median time 
from diagnosis of PMF to leukemic transformation was 52 weeks (range 33-365). None 
of the patients underwent definitive treatment for leukemia and was managed with 
palliative intent and all subsequently expired. The low rate of leukemic transformation is 
similar to what has been published earlier.105  
 
Progression to myelofibrosis, table 13 
 
A total of 7 (7.3%) patients of PV had progression to myelofibrosis and the time for 
documentation of progression from the time of diagnosis of PV was known in 5 patients. 
This ranged from 24-1383 weeks with a median of 537 weeks. Two of these patients had 
been diagnosed outside to have PV and when they came for review to us their disease had 
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progressed to myelofibrosis, hence these patients were labeled as post-PV MF. This 
prevalence too, is similar to what has been published previously.104  
 
JAK2V617F mutation positivity (table 14) 
Overall JAK2 mutation was positive in 134 (59%) patients. The highest rate of positivity 
was in PV, 64 (66.7%) which is, however, significantly lower than what has been 
reported previously. Whether this is due to an increased prevalence of other mutations of 
the JAK2 gene, or of the thrombopoietin receptor (Mpl) gene needs further investigation. 
All the patients of post-PV and post-ET MF were JAK2V617F positive.  
 
Cumulative incidence of thrombosis 
The cumulative incidence of thrombotic events in PV, ET, PMF and secondary 
erythrocytosis is depicted in figure 2 and was significantly different between these 
diseases (p<0.005). A significant proportion of patients with ET and PV had developed 
thrombosis before being diagnosed as having an MPN. 
 
Treatment 
Only about 2/3rd of patients with PV and secondary polycythemia underwent venesection 
as first line treatment. About 1/3rd of patient with PMF received thalidomide with 
prednisolone as first line therapy. Therapy led to a partial remission in at least 2/3rd of the 
patients similar to what has been published earlier.106  
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CONCLUSIONS 
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CONCLUSIONS 
 
• The myeloproliferative disorders are a heterogeneous group of diseases. 
• The mean age of PV, ET and PMF was about 10 years less in our analysis. 
• There was a significant male preponderance in the PV and PMF group which may 
be due to the social factors which influence medical care of the women in India.90, 
91  
• Several patients of PV had been diagnosed incidentally while being evaluated for 
an unrelated reason. 
• Except pruritus, which was low in our series, the other clinical features and 
response to treatment were similar to what has been published in the international 
literature. 
• The incidence of JAK2V617F mutation was lower than what has been reported in 
the international literature. 
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